Non-Hodgkins Lymphoma Clinical Trial
Patients with aggressive Non−Hodgkin−lymphoma treated at first diagnosis with chemotherapy
alone or combined chemo-radiotherapy can achieve high response rates. However, patients with
relapsed lymphoma still have a poor prognosis. High dose chemotherapy (HDCT) followed by
autologous stem cell transplantation (ASCT) is the treatment of choice for these patients.
An ASCT allows patients to receive much higher doses of chemotherapy than usual, to improve
the chances of curing the disease. The high−dose of chemotherapy destroys the cells in the
patients bone marrow and then the patients own cells from either the bone marrow or
peripheral blood are used to rescue the patient from intensive treatment. High−dose
chemotherapy with autologous stem cell (either bone marrow or peripheral blood)
transplantation is used in the treatment of Intermediate/High grade NHL with poor risk
disease and in second remission at the Royal Marsden Hospital.
The purpose of the present analysis is to determine independent prognostic factors
correlated with the long−term outcome of patients with NHL who received an ASCT between
January 1991 and June 2005. Accrual of eligible patients currently under follow−up will be
performed in clinic at the time of next appointment. All patients accrued will give informed
consent to participate in the study for retrospective case note review, after discussion
with a study investigator and after receiving a study information sheet. The results of the
analysis will be published in a peer−reviewed medical journal. This will include patients
treated at the royal Marsden Hospital only.
n/a
Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04240704 -
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
|
Phase 1 | |
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Recruiting |
NCT00807196 -
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00764829 -
Blood Samples to Evaluate Biomarkers of Donor Chimerism
|
N/A | |
| Completed |
NCT00726934 -
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
|
N/A | |
| Completed |
NCT01517581 -
Brown Fat Activity and White Fat Accumulation
|
N/A | |
| Completed |
NCT00193505 -
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
|
Phase 2 | |
| Terminated |
NCT01744912 -
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
|
Phase 1 | |
| Terminated |
NCT01500161 -
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
|
Phase 2 | |
| Active, not recruiting |
NCT03533283 -
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00001379 -
Treatment and Natural History Study of Lymphomatoid Granulomatosis
|
Phase 2 | |
| Completed |
NCT00574730 -
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
|
N/A | |
| Completed |
NCT00901225 -
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
|
Phase 2 | |
| Terminated |
NCT01598025 -
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
|
N/A | |
| Terminated |
NCT01326728 -
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
|
||
| Completed |
NCT01290549 -
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
|
Phase 1 | |
| Completed |
NCT00837200 -
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
|
Phase 2 | |
| Completed |
NCT00807677 -
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
| Terminated |
NCT00054834 -
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Terminated |
NCT00003500 -
Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma
|
Phase 2 |